KCTBASE

Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis.

Chakraborty, Chiranjib; Sharma, Ashish Ranjan; Bhattacharya, Manojit; Agoramoorthy, Govindasamy; Lee, Sang-Soo

Vaccines
2021Jun ; 9 ( 6 ) :.

PMID : 34199995

저자 상세정보

Chakraborty, Chiranjib - Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Barasat-Barrackpore Rd, Kolkata 700126, West Bengal, India.
Sharma, Ashish Ranjan - Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si 24252, Gangwon-do, Korea.
Bhattacharya, Manojit - Department of Zoology, Fakir Mohan University, Vyasa Vihar, Balasore 756020, Odisha, India.
Agoramoorthy, Govindasamy - College of Pharmacy and Health Care, Tajen University, Yanpu, Pingtung 907, Taiwan.
Lee, Sang-Soo - Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si 24252, Gangwon-do, Korea.

ABSTRACT

COVID-19 vaccination has started throughout the globe. The vaccination program has also begun in most Asian countries. This paper analyzed the Asian-origin COVID-19 vaccines and vaccination program status in Asia till March 2021 under three sections. In the first section, we mapped the approved vaccines that originated from Asia, their technological platforms, collaborations during vaccine development, and regulatory approval from other countries. We found that a total of eight Asian COVID-19 vaccines originated and got approval from three countries: China, India, and Russia. In the second section, we critically evaluated the recent progress of COVID-19 vaccination programs. We analyzed the overall vaccination status across the Asian region. We also calculated the cumulative COVID-19 vaccine doses administered in different Asian countries, vaccine rolling in 7-day average in various Asian countries, and COVID-19 vaccine per day doses administrated in several Asian countries. We found that China and India vaccinated the maximum number of people. Finally, we evaluated the factors affecting the COVID-19 vaccination program in Asia, such as vaccine hesitancy, basic reproduction numbers (R0) and vaccination campaigns, and the cost of the vaccines. Our analysis will assist the implementation of the COVID-19 vaccination program successfully in Asia.

keyword

Asia; COVID-19 vaccination; COVID-19 vaccines; factors infusing COVID-19 vaccination

MESH

링크

PubMed

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

The vaccine cost is an essential factor for the vaccination program, especially in low- and middle-income countries in Asia. The World Bank report in 2018 showed that 783 million people live in extreme poverty, and 42% of them are located in Asia. This article analyzed the cost of Asian-origin vaccines (Figure 13) and found that the Indian vaccine production company, the Serum Institute of India, produces the lowest-cost vaccine; All the Asian countries have started their COVID-19 vaccination with immense initiative and full efforts in small to medium populated countries and low to medium-income countries. However, vaccination programs are suffering from several unavoidable factors that hamper their progress, such as the cost of the COVID-19 vaccines, vaccine hesitancy, and vaccine illiteracy.

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

10.3390/vaccines9060600

KCD코드

ICD 03

건강보험코드